Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that specifically binds to human CD162 (PSGL-1). this binding leads to the downregulation and apoptosis of activated T cells, a mechanism currently in clinical development for the treatment of steroid-refractory acute graft-versus-host disease (GVHD), psoriasis, psoriatic arthritis, and ulcerative colitis.
Purity:
95%
CAS Number:
[2158362-38-8]
Target:
Apoptosis|||Others
* VAT and and shipping costs not included. Errors and price changes excepted